Overview

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban

Status:
Completed
Trial end date:
2020-08-26
Target enrollment:
Participant gender:
Summary
Evaluation of the performance of the 2MACE index in a population of nonvalvular atrial fibrillation (NVAF) patients treated with rivaroxaban in Spain
Details
Lead Sponsor:
Bayer
Collaborator:
Janssen Research & Development, LLC
Treatments:
Rivaroxaban